08:52 AM EST, 11/12/2025 (MT Newswires) -- Apellis Pharmaceuticals ( APLS ) said Wednesday that five-year data from a post hoc analysis of an extension study showed that its Syfovre injection delayed the progression of lesion growth by about 1.5 years in patients with nonsubfoveal geographic atrophy.

The company said results showed that both every-other-month and monthly dosing regimens delayed lesion growth in the patients, compared with the projected sham group.

Apellis said the safety profile of Syfovre through five years was consistent with prior data.

Shares of the company were up 2% in recent Wednesday premarket activity.